Skip to content

Study · Measured the body's own peptide · 2022

3 results

MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease.

Yaşar E, Çakmak T, Bayramoğlu A, Karakuş Y, Tekin S, Şekerci G, Türkoğlu C

European review for medical and pharmacological sciences1 Aug 2022Cited by 10 (Europe PMC)

PMID36066139 (opens in a new tab)DOI10.26355/eurrev_202208_29501 (opens in a new tab)PepBankPUB-36066139
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In adults with stable coronary artery disease, the body's own MOTS‑c levels were lower than in adults with normal coronary arteries.

    In plain wordsIn adults with stable coronary artery disease, natural MOTS‑c levels were lower than in adults with normal coronary arteries.

    Peptide
    MOTS-c
    Outcome
    DecreaseMOTS-c level in CAD versus normal coronary artery
    Study

    n = 184

    Comparator
    Patients with normal coronary artery
    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    We observed that the MOTS-c levels was lower in the CAD group (111±13 vs. 161±23, p<0.001).
    1 context sentence
    Summary · context
    Ninety-two consecutive patients with stable coronary artery disease (CAD+) and ninety-two consecutive patients with normal coronary artery (CAD-) were included.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In adults undergoing coronary assessment, the body's own MOTS‑c level was a significant independent predictor of coronary artery disease in multiple regression analysis.

    In plain wordsIn adults with and without coronary artery disease, natural MOTS‑c levels helped predict who had the disease.

    Peptide
    MOTS-c
    Outcome
    Not applicableMOTS-c level as independent predictor of CAD
    Study

    n = 184

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    The MOTS-c levels were also found to be significant independent predictors for CAD in multiple regression analysis (p<0.001).
    1 context sentence
    Summary · context
    Ninety-two consecutive patients with stable coronary artery disease (CAD+) and ninety-two consecutive patients with normal coronary artery (CAD-) were included.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    A MOTS‑c level of 130.9 or higher predicted coronary artery disease with 80.3% sensitivity and 73.2% specificity.

    In plain wordsA natural MOTS‑c level at or above a cut-off predicted coronary artery disease, with 80.3% sensitivity and 73.2% specificity.

    Peptide
    MOTS-c
    Outcome
    Not applicableDiagnostic accuracy of MOTS-c level for CAD
    Study

    n = 184

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    sensitivity
    80.3%
    MOTS-c >=130.9
    specificity
    73.2%
    MOTS-c >=130.9
    AUC
    0.858
    predicting CAD

    Source sentences

    Summary
    A MOTS-c levels ≥130.9 had 80.3% sensitivity and 73.2% specificity (area under the curve [AUC]: 0.858, 95% CI: 0.895-0.999, p<0.001) for predicting CAD.
    1 context sentence
    Summary · context
    Ninety-two consecutive patients with stable coronary artery disease (CAD+) and ninety-two consecutive patients with normal coronary artery (CAD-) were included.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.